激酶激活融合基因与IKZF1缺失对儿童高危B系急性淋巴细胞白血病的预后影响
在Dana-Farber癌症研究所ALL联盟方案05-001纳入的105例NCI高危、Ph阴性B-ALL患儿中,16例(15%)携带激酶激活融合(ABL类或JAK-STAT通路激活),其中69%伴IKZF1缺失;单变量分析中融合阳性和IKZF1缺失均与较差的无事件生存相关,多变量分析中IKZF1缺失保持统计学显著(HR 2.64,P=0.019)。
要点
- NCI高危Ph阴性B-ALL患儿中15%(16/105)携带激酶激活融合。
- 融合阳性患儿中69%伴IKZF1缺失(11例)。
- 多变量分析IKZF1缺失与较差EFS独立相关(HR 2.64,P=0.019)。
核心结论
- 研究结果支持对IKZF1改变的患者进行治疗强化,不论是否伴有激酶激活融合。
研究设计与样本
- 研究纳入Dana-Farber癌症研究所ALL联盟方案05-001的NCI高危、Ph阴性B-ALL患者,共筛查105例。
主要发现
- 105例筛查患者中16例(15%)携带ABL类融合(ETV6-ABL1、FOXP1-ABL1、SFPQ-ABL1各1例,ZC3HAV1-ABL2 1例)或JAK-STAT通路激活融合(P2RY8-CRLF2 8例,PAX5-JAK2 4例)。
- 携带融合的患者中69%(11例)伴IKZF1缺失。
- 单变量分析中,融合阳性和IKZF1缺失均与较差的无事件生存相关。
- 多变量分析中IKZF1缺失保持统计学显著(风险比2.64,P=0.019)。
临床怎么用
- 作者认为研究结果支持对IKZF1改变的患者进行治疗强化,不论是否伴有激酶激活融合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent chromosomal rearrangements carry prognostic significance in pediatric B-lineage acute lymphoblastic leukemia (B-ALL). Recent genome-wide analyses identified a high-risk B-ALL subtype characterized by a diverse spectrum of genetic alterations activating kinases and cytokine receptor genes. This subtype is associated with a poor prognosis when treated with conventional chemotherapy but has demonstrated sensitivity to the relevant tyrosine kinase inhibitors. We sought to determine the frequency of kinase-activating fusions among National Cancer Institute (NCI) high-risk, Ph-negative, B-ALL patients enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001 and to describe their associated clinical characteristics and outcomes. Among the 105 patients screened, 16 (15%) harbored an ABL-class fusion (ETV6-ABL1: n = 1; FOXP1-ABL1: n = 1; SFPQ-ABL1: n = 1; ZC3HAV1-ABL2: n = 1) or a fusion activating the JAK-STAT pathway (P2RY8-CRLF2: n = 8; PAX5-JAK2: n = 4). Sixty-nine percent of patients with an identified fusion had a concomitant IKZF1 deletion (n = 11). In univariate analysis, fusion-positivity and IKZF1 deletion were each associated with inferior event-free survival; IKZF1 deletion retained statistical significance in multivariable analysis (hazard ratio, 2.64; P = .019). Our findings support therapy intensification for IKZF1-altered patients, irrespective of the presence of a kinase-activating fusion.
引用
- Tran TH, Harris MH, Nguyen JV, et al. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Adv. 2018. PMID: 29507076. doi:10.1182/bloodadvances.2017014704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。